Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

Cell

Volumn 168, Issue 4, 2017, Pages 613-628

  McGranahan, Nicholas ^a,b   Swanton, Charles ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL HETEROGENEITY; CLONAL EVOLUTION; ECOSYSTEM; GENOME; GENOMIC INSTABILITY; HUMAN; LIFE HISTORY; MALIGNANT NEOPLASM; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENTIATION; TUMOR MICROENVIRONMENT; ANIMAL; DRUG RESISTANCE; GENETIC HETEROGENEITY; GENETICS; MUTATION; NEOPLASMS; PATHOLOGY;

ANIMALS; DRUG RESISTANCE, NEOPLASM; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMANS; MUTATION; NEOPLASMS;

EID: 85012110528     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.01.018     Document Type: Review

References (162)

1. Aceto, N., Bardia, A., Miyamoto, D.T., Donaldson, M.C., Wittner, B.S., Spencer, J.A., Yu, M., Pely, A., Engstrom, A., Zhu, H., et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158 (2014), 1110–1122.
2. Aerts, H.J., Velazquez, E.R., Leijenaar, R.T., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat. Commun., 5, 2014, 4006.
3. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.L., et al. Australian Pancreatic Cancer Genome Initiative ICGC Breast Cancer Consortium ICGC MMML-Seq Consortium, ICGC PedBrain. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
4. Alexandrov, L.B., Jones, P.H., Wedge, D.C., Sale, J.E., Campbell, P.J., Nik-Zainal, S., Stratton, M.R., Clock-like mutational processes in human somatic cells. Nat. Genet. 47 (2015), 1402–1407.
5. Anagnostou, V., Smith, K.N., Forde, P.M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. Evolution of Neoantigen Landscape During Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov., 2016, 10.1158/2159-8290.CD-16-0828 Published online December 28, 2016.
6. Anderson, K., Lutz, C., van Delft, F.W., Bateman, C.M., Guo, Y., Colman, S.M., Kempski, H., Moorman, A.V., Titley, I., Swansbury, J., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469 (2011), 356–361.
7. Andor, N., Graham, T.A., Jansen, M., Xia, L.C., Aktipis, C.A., Petritsch, C., Ji, H.P., Maley, C.C., Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat. Med. 22 (2016), 105–113.
8. Aryee, M.J., Liu, W., Engelmann, J.C., Nuhn, P., Gurel, M., Haffner, M.C., Esopi, D., Irizarry, R.A., Getzenberg, R.H., Nelson, W.G., et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med., 5, 2013, 169ra10.
9. Bashashati, A., Ha, G., Tone, A., Ding, J., Prentice, L.M., Roth, A., Rosner, J., Shumansky, K., Kalloger, S., Senz, J., et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol. 231 (2013), 21–34.
10. Bettegowda, C., Sausen, M., Leary, R.J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B.R., Wang, H., Luber, B., Alani, R.M., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med., 6, 2014, 224ra24.
11. Bhang, H.E., Ruddy, D.A., Krishnamurthy Radhakrishna, V., Caushi, J.X., Zhao, R., Hims, M.M., Singh, A.P., Kao, I., Rakiec, D., Shaw, P., et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21 (2015), 440–448.
12. Birkbak, N.J., Eklund, A.C., Li, Q., McClelland, S.E., Endesfelder, D., Tan, P., Tan, I.B., Richardson, A.L., Szallasi, Z., Swanton, C., Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 71 (2011), 3447–3452.
13. Bolli, N., Avet-Loiseau, H., Wedge, D.C., Van Loo, P., Alexandrov, L.B., Martincorena, I., Dawson, K.J., Iorio, F., Nik-Zainal, S., Bignell, G.R., et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun., 5, 2014, 2997.
14. Bozic, I., Nowak, M.A., Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc. Natl. Acad. Sci. USA 111 (2014), 15964–15968.
15. Bozic, I., Reiter, J.G., Allen, B., Antal, T., Chatterjee, K., Shah, P., Moon, Y.S., Yaqubie, A., Kelly, N., Le, D.T., et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife, 2, 2013, e00747.
16. Brastianos, P.K., Carter, S.L., Santagata, S., Cahill, D.P., Taylor-Weiner, A., Jones, R.T., Van Allen, E.M., Lawrence, M.S., Horowitz, P.M., Cibulskis, K., et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 5 (2015), 1164–1177.
17. Calbo, J., van Montfort, E., Proost, N., van Drunen, E., Beverloo, H.B., Meuwissen, R., Berns, A., A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19 (2011), 244–256.
18. Campbell, P.J., Yachida, S., Mudie, L.J., Stephens, P.J., Pleasance, E.D., Stebbings, L.A., Morsberger, L.A., Latimer, C., McLaren, S., Lin, M.L., et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467 (2010), 1109–1113.
19. Carreira, S., Romanel, A., Goodall, J., Grist, E., Ferraldeschi, R., Miranda, S., Prandi, D., Lorente, D., Frenel, J.S., Pezaro, C., et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl. Med., 6, 2014, 254ra125.
20. Carter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P.W., Onofrio, R.C., Winckler, W., Weir, B.A., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30 (2012), 413–421.
21. Chen, H., He, X., The Convergent Cancer Evolution toward a Single Cellular Destination. Mol. Biol. Evol. 33 (2016), 4–12.
22. Chen, G., Mulla, W.A., Kucharavy, A., Tsai, H.J., Rubinstein, B., Conkright, J., McCroskey, S., Bradford, W.D., Weems, L., Haug, J.S., et al. Targeting the adaptability of heterogeneous aneuploids. Cell 160 (2015), 771–784.
23. Cheung, K.J., Padmanaban, V., Silvestri, V., Schipper, K., Cohen, J.D., Fairchild, A.N., Gorin, M.A., Verdone, J.E., Pienta, K.J., Bader, J.S., Ewald, A.J., Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc. Natl. Acad. Sci. USA 113 (2016), E854–E863.
24. Cleary, A.S., Leonard, T.L., Gestl, S.A., Gunther, E.J., Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 508 (2014), 113–117.
25. Conway Morris, S., Life's solution: inevtiable humans in a lonely universe. 2003, Cambridge University Press, New York.
26. Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., Ferrara, N., PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15 (2009), 21–34.
27. Darwin, C., On the Origin of Species by Means of Natural Selection, Or, The Preservation of Favoured Races in the Struggle for Life. 1859, J. Murray.
28. Das Thakur, M., Salangsang, F., Landman, A.S., Sellers, W.R., Pryer, N.K., Levesque, M.P., Dummer, R., McMahon, M., Stuart, D.D., Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494 (2013), 251–255.
29. Dawson, S.J., Tsui, D.W., Murtaza, M., Biggs, H., Rueda, O.M., Chin, S.F., Dunning, M.J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368 (2013), 1199–1209.
30. de Bruin, E.C., McGranahan, N., Mitter, R., Salm, M., Wedge, D.C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A.J., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346 (2014), 251–256.
31. Deshwar, A.G., Vembu, S., Yung, C.K., Jang, G.H., Stein, L., Morris, Q., PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol., 16, 2015, 35.
32. Dewhurst, S.M., McGranahan, N., Burrell, R.A., Rowan, A.J., Grönroos, E., Endesfelder, D., Joshi, T., Mouradov, D., Gibbs, P., Ward, R.L., et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4 (2014), 175–185.
33. Driessens, G., Beck, B., Caauwe, A., Simons, B.D., Blanpain, C., Defining the mode of tumour growth by clonal analysis. Nature 488 (2012), 527–530.
34. Eckert, M.A., Pan, S., Hernandez, K.M., Loth, R.M., Andrade, J., Volchenboum, S.L., Faber, P., Montag, A., Lastra, R., Peter, M.E., et al. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 6 (2016), 1342–1351.
35. Eleveld, T.F., Oldridge, D.A., Bernard, V., Koster, J., Daage, L.C., Diskin, S.J., Schild, L., Bentahar, N.B., Bellini, A., Chicard, M., et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat. Genet. 47 (2015), 864–871.
36. Enriquez-Navas, P.M., Kam, Y., Das, T., Hassan, S., Silva, A., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R.J., Gatenby, R.A., Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl. Med., 8, 2016, 327ra24.
37. Faltas, B.M., Prandi, D., Tagawa, S.T., Molina, A.M., Nanus, D.M., Sternberg, C., Rosenberg, J., Mosquera, J.M., Robinson, B., Elemento, O., et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet. 48 (2016), 1490–1499.
38. Fedorenko, I.V., Abel, E.V., Koomen, J.M., Fang, B., Wood, E.R., Chen, Y.A., Fisher, K.J., Iyengar, S., Dahlman, K.B., Wargo, J.A., et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene 35 (2016), 1225–1235.
39. Fischer, A., Vázquez-García, I., Illingworth, C.J., Mustonen, V., High-definition reconstruction of clonal composition in cancer. Cell Rep. 7 (2014), 1740–1752.
40. Fisher, R., Horswell, S., Rowan, A., Salm, M.P., de Bruin, E.C., Gulati, S., McGranahan, N., Stares, M., Gerlinger, M., Varela, I., et al. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biol., 15, 2014, 433.
41. Fojo, T., Mailankody, S., Lo, A., Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol. Head Neck Surg. 140 (2014), 1225–1236.
42. Francis, J.M., Zhang, C.Z., Maire, C.L., Jung, J., Manzo, V.E., Adalsteinsson, V.A., Homer, H., Haidar, S., Blumenstiel, B., Pedamallu, C.S., et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 4 (2014), 956–971.
43. Fu, F., Nowak, M.A., Bonhoeffer, S., Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput. Biol., 11, 2015, e1004142.
44. Fujiwara, T., Bandi, M., Nitta, M., Ivanova, E.V., Bronson, R.T., Pellman, D., Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437 (2005), 1043–1047.
45. Gao, R., Davis, A., McDonald, T.O., Sei, E., Shi, X., Wang, Y., Tsai, P.C., Casasent, A., Waters, J., Zhang, H., et al. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat. Genet. 48 (2016), 1119–1130.
46. Gatenby, R.A., Silva, A.S., Gillies, R.J., Frieden, B.R., Adaptive therapy. Cancer Res. 69 (2009), 4894–4903.
47. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
48. Gerlinger, M., Horswell, S., Larkin, J., Rowan, A.J., Salm, M.P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C.R., et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46 (2014), 225–233.
49. Gerlinger, M., McGranahan, N., Dewhurst, S.M., Burrell, R.A., Tomlinson, I., Swanton, C., Cancer: evolution within a lifetime. Annu. Rev. Genet. 48 (2014), 215–236.
50. Gilbert, L.A., Hemann, M.T., DNA damage-mediated induction of a chemoresistant niche. Cell 143 (2010), 355–366.
51. Goldschmidt, R., The Material Basis of Evolution: Reissued. Second Edition, 1982, Yale University.
52. Gould, S.J., Wonderful life: the Burgess Shale and the nature of history. 2000, Random House.
53. Greaves, M., Evolutionary determinants of cancer. Cancer Discov. 5 (2015), 806–820.
54. Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L.B., Tubio, J.M., Papaemmanuil, E., Brewer, D.S., Kallio, H.M., Högnäs, G., Annala, M., et al., ICGC Prostate UK Group. The evolutionary history of lethal metastatic prostate cancer. Nature 520 (2015), 353–357.
55. Ha, G., Roth, A., Khattra, J., Ho, J., Yap, D., Prentice, L.M., Melnyk, N., McPherson, A., Bashashati, A., Laks, E., et al. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res. 24 (2014), 1881–1893.
56. Haber, D.A., Velculescu, V.E., Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 4 (2014), 650–661.
57. Hao, J.J., Lin, D.C., Dinh, H.Q., Mayakonda, A., Jiang, Y.Y., Chang, C., Jiang, Y., Lu, C.C., Shi, Z.Z., Xu, X., et al. Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat. Genet. 48 (2016), 1500–1507.
58. Harbst, K., Lauss, M., Cirenajwis, H., Isaksson, K., Rosengren, F., Törngren, T., Kvist, A., Johansson, M.C., Vallon-Christersson, J., Baldetorp, B., et al. Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma. Cancer Res. 76 (2016), 4765–4774.
59. Hartkopf, A.D., Stefanescu, D., Wallwiener, M., Hahn, M., Becker, S., Solomayer, E.F., Fehm, T.N., Brucker, S.Y., Taran, F.A., Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer. Breast Cancer Res. Treat. 147 (2014), 345–351.
60. Hata, A.N., Niederst, M.J., Archibald, H.L., Gomez-Caraballo, M., Siddiqui, F.M., Mulvey, H.E., Maruvka, Y.E., Ji, F., Bhang, H.E., Krishnamurthy Radhakrishna, V., et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22 (2016), 262–269.
61. Hill, B.T., Potential of continuous tumour cell lines for establishing patterns of cross-resistance and collateral sensitivity in vitro. Drugs Exp. Clin. Res. 12 (1986), 293–298.
62. Hirata, E., Girotti, M.R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., Sahai, E., Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. Cancer Cell 27 (2015), 574–588.
63. Hobor, S., Van Emburgh, B.O., Crowley, E., Misale, S., Di Nicolantonio, F., Bardelli, A., TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. Clin. Cancer Res. 20 (2014), 6429–6438.
64. Humphries, A., Cereser, B., Gay, L.J., Miller, D.S., Das, B., Gutteridge, A., Elia, G., Nye, E., Jeffery, R., Poulsom, R., et al. Lineage tracing reveals multipotent stem cells maintain human adenomas and the pattern of clonal expansion in tumor evolution. Proc. Natl. Acad. Sci. USA 110 (2013), E2490–E2499.
65. Huxley, J., The Biological Aspects of Cancer. 1958, Harcourt, Brace, New York.
66. Inda, M.M., Bonavia, R., Mukasa, A., Narita, Y., Sah, D.W., Vandenberg, S., Brennan, C., Johns, T.G., Bachoo, R., Hadwiger, P., et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 24 (2010), 1731–1745.
67. Jamal-Hanjani, M., Wilson, G.A., Horswell, S., Mitter, R., Sakarya, O., Constantin, T., Salari, R., Kirkizlar, E., Sigurjonsson, S., Pelham, R., et al. Detection of Ubiquitous and Heterogeneous Mutations in Cell-Free DNA from Patients with Early-Stage Non-Small-Cell Lung Cancer. Ann. Oncol. 27 (2016), 862–867.
68. Jensen, P.B., Holm, B., Sorensen, M., Christensen, I.J., Sehested, M., In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br. J. Cancer 75 (1997), 869–877.
69. Jiang, Y., Qiu, Y., Minn, A.J., Zhang, N.R., Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing. Proc. Natl. Acad. Sci. USA 113 (2016), E5528–E5537.
70. Johnson, B.E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C.Y., Fouse, S.D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343 (2014), 189–193.
71. Ju, Y.S., Alexandrov, L.B., Gerstung, M., Martincorena, I., Nik-Zainal, S., Ramakrishna, M., Davies, H.R., Papaemmanuil, E., Gundem, G., Shlien, A., et al. ICGC Breast Cancer Group ICGC Chronic Myeloid Disorders Group, ICGC Prostate Cancer Group. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. eLife, 3, 2014, e02935.
72. Junttila, M.R., de Sauvage, F.J., Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501 (2013), 346–354.
73. Juric, D., Castel, P., Griffith, M., Griffith, O.L., Won, H.H., Ellis, H., Ebbesen, S.H., Ainscough, B.J., Ramu, A., Iyer, G., et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 518 (2015), 240–244.
74. Kim, H., Zheng, S., Amini, S.S., Virk, S.M., Mikkelsen, T., Brat, D.J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 25 (2015), 316–327.
75. Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., Schreiber, R.D., Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007), 903–907.
76. Kostadinov, R.L., Kuhner, M.K., Li, X., Sanchez, C.A., Galipeau, P.C., Paulson, T.G., Sather, C.L., Srivastava, A., Odze, R.D., Blount, P.L., et al. NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet., 9, 2013, e1003553.
77. Kumar, A., Coleman, I., Morrissey, C., Zhang, X., True, L.D., Gulati, R., Etzioni, R., Bolouri, H., Montgomery, B., White, T., et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22 (2016), 369–378.
78. Lalonde, E., Ishkanian, A.S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M.J., Halim, S., Lamb, A.D., Moon, N.C., et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 15 (2014), 1521–1532.
79. Lamy, P., Nordentoft, I., Birkenkamp-Demtröder, K., Thomsen, M.B., Villesen, P., Vang, S., Hedegaard, J., Borre, M., Jensen, J.B., Høyer, S., et al. Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. Cancer Res. 76 (2016), 5894–5906.
80. Landau, D.A., Carter, S.L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M.S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152 (2013), 714–726.
81. Law, E.K., Sieuwerts, A.M., LaPara, K., Leonard, B., Starrett, G.J., Molan, A.M., Temiz, N.A., Vogel, R.I., Meijer-van Gelder, M.E., Sweep, F.C., et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci. Adv., 2, 2016, e1601737.
82. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
83. Ling, S., Hu, Z., Yang, Z., Yang, F., Li, Y., Lin, P., Chen, K., Dong, L., Cao, L., Tao, Y., et al. Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc. Natl. Acad. Sci. USA 112 (2015), E6496–E6505.
84. Lipinski, K.A., Barber, L.J., Davies, M.N., Ashenden, M., Sottoriva, A., Gerlinger, M., Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine. Trends Cancer 2 (2016), 49–63.
85. Lord, C.J., Ashworth, A., BRCAness revisited. Nat. Rev. Cancer 16 (2016), 110–120.
86. Maddipati, R., Stanger, B.Z., Pancreatic Cancer Metastases Harbor Evidence of Polyclonality. Cancer Discov. 5 (2015), 1086–1097.
87. Makohon-Moore, A.P., Zhang, M., Reiter, J.G., Bozic, I., Allen, B., Kundu, D., Chatterjee, K., Wong, F., Jiao, Y., Kohutek, Z.A., et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat. Genet., 2017, 10.1038/ng.3764 Published online January 16, 2017.
88. Maley, C.C., Galipeau, P.C., Finley, J.C., Wongsurawat, V.J., Li, X., Sanchez, C.A., Paulson, T.G., Blount, P.L., Risques, R.A., Rabinovitch, P.S., Reid, B.J., Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38 (2006), 468–473.
89. Malhotra, A., Lindberg, M., Faust, G.G., Leibowitz, M.L., Clark, R.A., Layer, R.M., Quinlan, A.R., Hall, I.M., Breakpoint profiling of 64 cancer genomes reveals numerous complex rearrangements spawned by homology-independent mechanisms. Genome Res. 23 (2013), 762–776.
90. Mao, Q., Zhang, Y., Fu, X., Xue, J., Guo, W., Meng, M., Zhou, Z., Mo, X., Lu, Y., A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy. J. Cancer Res. Clin. Oncol. 139 (2013), 211–222.
91. Martinez, P., Birkbak, N.J., Gerlinger, M., McGranahan, N., Burrell, R.A., Rowan, A.J., Joshi, T., Fisher, R., Larkin, J., Szallasi, Z., Swanton, C., Parallel evolution of tumour subclones mimics diversity between tumours. J. Pathol. 230 (2013), 356–364.
92. Marusyk, A., Tabassum, D.P., Altrock, P.M., Almendro, V., Michor, F., Polyak, K., Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514 (2014), 54–58.
93. Mayers, J.R., Torrence, M.E., Danai, L.V., Papagiannakopoulos, T., Davidson, S.M., Bauer, M.R., Lau, A.N., Ji, B.W., Dixit, P.D., Hosios, A.M., et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353 (2016), 1161–1165.
94. Mazor, T., Pankov, A., Johnson, B.E., Hong, C., Hamilton, E.G., Bell, R.J., Smirnov, I.V., Reis, G.F., Phillips, J.J., Barnes, M.J., et al. DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell 28 (2015), 307–317.
95. Mazor, T., Pankov, A., Song, J.S., Costello, J.F., Intratumoral Heterogeneity of the Epigenome. Cancer Cell 29 (2016), 440–451.
96. McDermott, D.H., Gao, J.L., Liu, Q., Siwicki, M., Martens, C., Jacobs, P., Velez, D., Yim, E., Bryke, C.R., Hsu, N., et al. Chromothriptic cure of WHIM syndrome. Cell 160 (2015), 686–699.
97. McGranahan, N., Burrell, R.A., Endesfelder, D., Novelli, M.R., Swanton, C., Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep. 13 (2012), 528–538.
98. McGranahan, N., Favero, F., de Bruin, E.C., Birkbak, N.J., Szallasi, Z., Swanton, C., Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med., 7, 2015, 283ra54.
99. McGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
100. McPherson, A., Roth, A., Laks, E., Masud, T., Bashashati, A., Zhang, A.W., Ha, G., Biele, J., Yap, D., Wan, A., et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48 (2016), 758–767.
101. Medema, J.P., de Jong, J., van Hall, T., Melief, C.J., Offringa, R., Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190 (1999), 1033–1038.
102. Mehine, M., Kaasinen, E., Mäkinen, N., Katainen, R., Kämpjärvi, K., Pitkänen, E., Heinonen, H.R., Bützow, R., Kilpivaara, O., Kuosmanen, A., et al. Characterization of uterine leiomyomas by whole-genome sequencing. N. Engl. J. Med. 369 (2013), 43–53.
103. Melchor, L., Brioli, A., Wardell, C.P., Murison, A., Potter, N.E., Kaiser, M.F., Fryer, R.A., Johnson, D.C., Begum, D.B., Hulkki Wilson, S., et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 28 (2014), 1705–1715.
104. Merlo, L.M., Shah, N.A., Li, X., Blount, P.L., Vaughan, T.L., Reid, B.J., Maley, C.C., A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. (Phila.) 3 (2010), 1388–1397.
105. Miller, C.A., White, B.S., Dees, N.D., Griffith, M., Welch, J.S., Griffith, O.L., Vij, R., Tomasson, M.H., Graubert, T.A., Walter, M.J., et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput. Biol., 10, 2014, e1003665.
106. Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486 (2012), 532–536.
107. Monajemi, M., Woodworth, C.F., Zipperlen, K., Gallant, M., Grant, M.D., Larijani, M., Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells. PLoS ONE, 9, 2014, e93428.
108. Morrison, C.D., Liu, P., Woloszynska-Read, A., Zhang, J., Luo, W., Qin, M., Bshara, W., Conroy, J.M., Sabatini, L., Vedell, P., et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc. Natl. Acad. Sci. USA 111 (2014), E672–E681.
109. Morrissy, A.S., Garzia, L., Shih, D.J., Zuyderduyn, S., Huang, X., Skowron, P., Remke, M., Cavalli, F.M., Ramaswamy, V., Lindsay, P.E., et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature 529 (2016), 351–357.
110. Murtaza, M., Dawson, S.J., Tsui, D.W., Gale, D., Forshew, T., Piskorz, A.M., Parkinson, C., Chin, S.F., Kingsbury, Z., Wong, A.S., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497 (2013), 108–112.
111. Murugaesu, N., Wilson, G.A., Birkbak, N.J., Watkins, T.B., McGranahan, N., Kumar, S., Abbassi-Ghadi, N., Salm, M., Mitter, R., Horswell, S., et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 5 (2015), 821–831.
112. Nadeu, F., Delgado, J., Royo, C., Baumann, T., Stankovic, T., Pinyol, M., Jares, P., Navarro, A., Martín-García, D., Beà, S., et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 127 (2016), 2122–2130.
113. Natrajan, R., Sailem, H., Mardakheh, F.K., Arias Garcia, M., Tape, C.J., Dowsett, M., Bakal, C., Yuan, Y., Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis. PLoS Med., 13, 2016, e1001961.
114. Nik-Zainal, S., Alexandrov, L.B., Wedge, D.C., Van Loo, P., Greenman, C.D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L.A., et al., Breast Cancer Working Group of the International Cancer Genome Consortium. Mutational processes molding the genomes of 21 breast cancers. Cell 149 (2012), 979–993.
115. Nikbakht, H., Panditharatna, E., Mikael, L.G., Li, R., Gayden, T., Osmond, M., Ho, C.Y., Kambhampati, M., Hwang, E.I., Faury, D., et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat. Commun., 7, 2016, 11185.
116. Nones, K., Waddell, N., Wayte, N., Patch, A.M., Bailey, P., Newell, F., Holmes, O., Fink, J.L., Quinn, M.C., Tang, Y.H., et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun., 5, 2014, 5224.
117. Notta, F., Chan-Seng-Yue, M., Lemire, M., Li, Y., Wilson, G.W., Connor, A.A., Denroche, R.E., Liang, S.B., Brown, A.M., Kim, J.C., et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538 (2016), 378–382.
118. Nowell, P.C., The clonal evolution of tumor cell populations. Science 194 (1976), 23–28.
119. Okosun, J., Bödör, C., Wang, J., Araf, S., Yang, C.Y., Pan, C., Boller, S., Cittaro, D., Bozek, M., Iqbal, S., et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 46 (2014), 176–181.
120. Ortmann, C.A., Kent, D.G., Nangalia, J., Silber, Y., Wedge, D.C., Grinfeld, J., Baxter, E.J., Massie, C.E., Papaemmanuil, E., Menon, S., et al. Effect of mutation order on myeloproliferative neoplasms. N. Engl. J. Med. 372 (2015), 601–612.
121. Pallasch, C.P., Leskov, I., Braun, C.J., Vorholt, D., Drake, A., Soto-Feliciano, Y.M., Bent, E.H., Schwamb, J., Iliopoulou, B., Kutsch, N., et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 156 (2014), 590–602.
122. Park, S., Lehner, B., Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types. Mol. Syst. Biol., 11, 2015, 824.
123. Pearson, A., Smyth, E., Babina, I.S., Herrera-Abreu, M.T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N.R., Geh, C., Rooney, C., et al. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discov. 6 (2016), 838–851.
124. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
125. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
126. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B.S., Swanton, C., DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol., 17, 2016, 31.
127. Roth, A., Khattra, J., Yap, D., Wan, A., Laks, E., Biele, J., Ha, G., Aparicio, S., Bouchard-Côté, A., Shah, S.P., PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11 (2014), 396–398.
128. Roth, A., McPherson, A., Laks, E., Biele, J., Yap, D., Wan, A., Smith, M.A., Nielsen, C.B., McAlpine, J.N., Aparicio, S., et al. Clonal genotype and population structure inference from single-cell tumor sequencing. Nat. Methods 13 (2016), 573–576.
129. Russo, M., Siravegna, G., Blaszkowsky, L.S., Corti, G., Crisafulli, G., Ahronian, L.G., Mussolin, B., Kwak, E.L., Buscarino, M., Lazzari, L., et al. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov. 6 (2016), 147–153.
130. Schwarz, R.F., Ng, C.K., Cooke, S.L., Newman, S., Temple, J., Piskorz, A.M., Gale, D., Sayal, K., Murtaza, M., Baldwin, P.J., et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med., 12, 2015, e1001789.
131. Selmecki, A.M., Maruvka, Y.E., Richmond, P.A., Guillet, M., Shoresh, N., Sorenson, A.L., De, S., Kishony, R., Michor, F., Dowell, R., Pellman, D., Polyploidy can drive rapid adaptation in yeast. Nature 519 (2015), 349–352.
132. Shaw, A.T., Friboulet, L., Leshchiner, I., Gainor, J.F., Bergqvist, S., Brooun, A., Burke, B.J., Deng, Y.L., Liu, W., Dardaei, L., et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N. Engl. J. Med. 374 (2016), 54–61.
133. Shen, R., Seshan, V.E., FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res., 44, 2016, e131.
134. Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R.C., Moriceau, G., Chodon, T., Guo, R., Johnson, D.B., Dahlman, K.B., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4 (2014), 80–93.
135. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J. Clin. 63 (2013), 11–30.
136. Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21 (2015), 795–801.
137. Smith, M.P., Sanchez-Laorden, B., O'Brien, K., Brunton, H., Ferguson, J., Young, H., Dhomen, N., Flaherty, K.T., Frederick, D.T., Cooper, Z.A., et al. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. Cancer Discov. 4 (2014), 1214–1229.
138. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
139. Sottoriva, A., Kang, H., Ma, Z., Graham, T.A., Salomon, M.P., Zhao, J., Marjoram, P., Siegmund, K., Press, M.F., Shibata, D., Curtis, C., A Big Bang model of human colorectal tumor growth. Nat. Genet. 47 (2015), 209–216.
140. Stachler, M.D., Taylor-Weiner, A., Peng, S., McKenna, A., Agoston, A.T., Odze, R.D., Davison, J.M., Nason, K.S., Loda, M., Leshchiner, I., et al. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat. Genet. 47 (2015), 1047–1055.
141. Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., Du, J., Davis, A., Mongare, M.M., Gould, J., Frederick, D.T., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487 (2012), 500–504.
142. Su, K.Y., Chen, H.Y., Li, K.C., Kuo, M.L., Yang, J.C., Chan, W.K., Ho, B.C., Chang, G.C., Shih, J.Y., Yu, S.L., Yang, P.C., Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J. Clin. Oncol. 30 (2012), 433–440.
143. Sun, Y., Campisi, J., Higano, C., Beer, T.M., Porter, P., Coleman, I., True, L., Nelson, P.S., Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18 (2012), 1359–1368.
144. Tavora, B., Reynolds, L.E., Batista, S., Demircioglu, F., Fernandez, I., Lechertier, T., Lees, D.M., Wong, P.P., Alexopoulou, A., Elia, G., et al. Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature 514 (2014), 112–116.
145. Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H. 2nd, Treacy, D., Trombetta, J.J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352 (2016), 189–196.
146. Tomasetti, C., Vogelstein, B., Parmigiani, G., Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc. Natl. Acad. Sci. USA 110 (2013), 1999–2004.
147. Turajlic, S., Swanton, C., Metastasis as an evolutionary process. Science 352 (2016), 169–175.
148. Turke, A.B., Zejnullahu, K., Wu, Y.L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17 (2010), 77–88.
149. Uchi, R., Takahashi, Y., Niida, A., Shimamura, T., Hirata, H., Sugimachi, K., Sawada, G., Iwaya, T., Kurashige, J., Shinden, Y., et al. Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. PLoS Genet., 12, 2016, e1005778.
150. Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M.H., Goldinger, S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
151. Verdegaal, E.M., de Miranda, N.F., Visser, M., Harryvan, T., van Buuren, M.M., Andersen, R.S., Hadrup, S.R., van der Minne, C.E., Schotte, R., Spits, H., et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536 (2016), 91–95.
152. Voss, M.H., Hakimi, A.A., Pham, C.G., Brannon, A.R., Chen, Y.B., Cunha, L.F., Akin, O., Liu, H., Takeda, S., Scott, S.N., et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin. Cancer Res. 20 (2014), 1955–1964.
153. Waclaw, B., Bozic, I., Pittman, M.E., Hruban, R.H., Vogelstein, B., Nowak, M.A., A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature 525 (2015), 261–264.
154. Wallace, A.R. (1867). Mimicry, and Other Protective Resemblances Among Animals. Westminster Review.
155. Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D.I., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.J., et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48 (2016), 768–776.
156. Williams, M.J., Werner, B., Barnes, C.P., Graham, T.A., Sottoriva, A., Identification of neutral tumor evolution across cancer types. Nat. Genet. 48 (2016), 238–244.
157. Xue, R., Li, R., Guo, H., Guo, L., Su, Z., Ni, X., Qi, L., Zhang, T., Li, Q., Zhang, Z., et al. Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma. Gastroenterology 150 (2016), 998–1008.
158. Yates, L.R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P., Aas, T., Alexandrov, L.B., Larsimont, D., Davies, H., et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21 (2015), 751–759.
159. Yuan, Y., Failmezger, H., Rueda, O.M., Ali, H.R., Gräf, S., Chin, S.F., Schwarz, R.F., Curtis, C., Dunning, M.J., Bardwell, H., et al. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci. Transl. Med., 4, 2012, 157ra143.
160. Zack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G., Tabak, B., Lawrence, M.S., Zhsng, C.Z., Wala, J., Mermel, C.H., et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45 (2013), 1134–1140.
161. Zhang, J., Fujimoto, J., Zhang, J., Wedge, D.C., Song, X., Zhang, J., Seth, S., Chow, C.W., Cao, Y., Gumbs, C., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346 (2014), 256–259.
162. Zhao, B., Sedlak, J.C., Srinivas, R., Creixell, P., Pritchard, J.R., Tidor, B., Lauffenburger, D.A., Hemann, M.T., Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell 165 (2016), 234–246.